Yunnan Baiyao Group Co Ltd
SZSE:000538
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Yunnan Baiyao Group Co Ltd
Long-Term Debt
Yunnan Baiyao Group Co Ltd
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Long-Term Debt
¥779.6m
|
CAGR 3-Years
39%
|
CAGR 5-Years
84%
|
CAGR 10-Years
-1%
|
|
|
C
|
CSPC Pharmaceutical Group Ltd
HKEX:1093
|
Long-Term Debt
¥180.7m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
-14%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Long-Term Debt
¥47.6m
|
CAGR 3-Years
-78%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Long-Term Debt
¥43.3m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Long-Term Debt
¥4.2B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
0%
|
CAGR 10-Years
46%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Long-Term Debt
¥1.2B
|
CAGR 3-Years
129%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Yunnan Baiyao Group Co Ltd
Glance View
Yunnan Baiyao Group Co Ltd is a captivating story of fusion between traditional Chinese medicine and modern business acumen. Rooted in Yunnan province's rich heritage, the company traces its origins back to the early 1900s when a local healer discovered a potent remedy for addressing wounds and reducing bleeding. Over the years, this original formula, a tightly-kept secret, evolved into a cornerstone product that propelled Yunnan Baiyao into the spotlight. As the company expanded, it embraced an adept strategy of integrating traditional formulations with contemporary pharmaceutical practices, enabling it to carve out a niche within the global health sector. Today, Yunnan Baiyao Group boasts a diversified portfolio that extends beyond its flagship product to include various health care, personal care, and even veterinary offerings. Its revenue model intricately weaves together streams from over-the-counter remedies, prescription medications, and consumer healthcare products. The company's innovative stride into the realms of cosmetics and toothpaste indicates its agility in adapting ancient knowledge for contemporary consumer demands. Strategic marketing emphasizes the unique heritage and trusted efficacy of its products, helping Yunnan Baiyao solidify its standing in a competitive market. As it continues to grow, the group remains a compelling example of how deeply-rooted tradition can be harnessed to drive a modern enterprise to sustained profitability.
See Also
What is Yunnan Baiyao Group Co Ltd's Long-Term Debt?
Long-Term Debt
779.6m
CNY
Based on the financial report for Dec 31, 2025, Yunnan Baiyao Group Co Ltd's Long-Term Debt amounts to 779.6m CNY.
What is Yunnan Baiyao Group Co Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
-1%
Over the last year, the Long-Term Debt growth was 0%. The average annual Long-Term Debt growth rates for Yunnan Baiyao Group Co Ltd have been 39% over the past three years , 84% over the past five years , and -1% over the past ten years .